Alnylam Pharmaceuticals Inc (ALNY)vsRAPT Therapeutics Inc (RAPT)
ALNY
Alnylam Pharmaceuticals Inc
$312.17
+0.34%
HEALTHCARE · Cap: $42.29B
RAPT
RAPT Therapeutics Inc
$58.02
0.00%
HEALTHCARE · Cap: $1.68B
Smart Verdict
WallStSmart Research — data-driven comparison
ALNY leads profitability with a 8.4% profit margin vs 0.0%. ALNY earns a higher WallStSmart Score of 49/100 (D+).
ALNY
Hold49
out of 100
Grade: D+
RAPT
Avoid21
out of 100
Grade: F
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
-1934.6%
Fair Value
$15.84
Current Price
$312.17
$296.33 premium
Intrinsic value data unavailable for RAPT.
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Every $100 of equity generates 73 in profit
Revenue surging 84.9% year-over-year
Conservative balance sheet, low leverage
Areas to Watch
0.0% earnings growth
Premium valuation, high expectations priced in
Trading at 52.4x book value
0.0% earnings growth
Smaller company, higher risk/reward
0.0% margin — thin
Operating margin of 0.0%
Comparative Analysis Report
WallStSmart ResearchBull Case : ALNY
The strongest argument for ALNY centers on Return on Equity, Revenue Growth. Revenue growth of 84.9% demonstrates continued momentum.
Bull Case : RAPT
The strongest argument for RAPT centers on Debt/Equity.
Bear Case : ALNY
The primary concerns for ALNY are EPS Growth, P/E Ratio, Price/Book. A P/E of 136.9x leaves little room for execution misses.
Bear Case : RAPT
The primary concerns for RAPT are EPS Growth, Market Cap, Profit Margin.
Key Dynamics to Monitor
ALNY profiles as a hypergrowth stock while RAPT is a value play — different risk/reward profiles.
RAPT carries more volatility with a beta of 0.44 — expect wider price swings.
ALNY is growing revenue faster at 84.9% — sustainability is the question.
ALNY generates stronger free cash flow (140M), providing more financial flexibility.
Bottom Line
ALNY scores higher overall (49/100 vs 21/100) and 84.9% revenue growth. Both earn "Hold" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Alnylam Pharmaceuticals Inc
HEALTHCARE · BIOTECHNOLOGY · USA
Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.
RAPT Therapeutics Inc
HEALTHCARE · BIOTECHNOLOGY · USA
RAPT Therapeutics, Inc., a clinical-stage immunology-based biopharmaceutical company, focuses on discovering, developing and commercializing oral small molecule therapies for patients with unmet needs in oncology and inflammatory diseases. The company is headquartered in South San Francisco, California.
Visit Website →Compare with Other BIOTECHNOLOGY Stocks
Want to dig deeper into these stocks?